Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

Autor: Javier Cortes, Eric P Winer, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalves, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Stephanie Hund, Karina Kulangara, Vassiliki Karantza, Jaime A Mejia, Junshui Ma, Petar Jelinic, Lingkang Huang, Scott K Pruitt, Kenneth Emancipator

Publikováno v: The Journal of Pathology: Clinical Research, Vol 10, Iss 3, Pp n/a-n/a (2024)

Abstract The efficacy of pembrolizumab monotherapy versus chemotherapy increased with increasing programmed death ligand 1 (PD‐L1) expression, as quantified by combined positive score (CPS; PD‐L1 expression on both tumour cells and immune cells)

Externí odkaz: https://doaj.org/article/42c035448af94e8fbfc51bd921ef67f3

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)

Autor: Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Koung Jin Suh, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, Jae Ho Byun, Jin Hyun Park, Gyeong-Won Lee, Keun Seok Lee, Joohyuk Sohn, Kyung Hae Jung, In Hae Park

Publikováno v: Breast, Vol 65, Iss , Pp 172-178 (2022)

We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.

Externí odkaz: https://doaj.org/article/330f949c2ee044c8b4039cf8ac994503

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Autor: Peter Schmid, Marie-Paule Sablin, Jonas Bergh, Seock-Ah Im, Yen-Shen Lu, Noelia Martínez, Patrick Neven, Keun Seok Lee, Serafín Morales, J. Alejandro Pérez-Fidalgo, Douglas Adamson, Anthony Gonçalves, Aleix Prat, Guy Jerusalem, Laura Schlieker, Rosa-Maria Espadero, Thomas Bogenrieder, Dennis Chin-Lun Huang, John Crown, Javier Cortés

Publikováno v: Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)

Abstract Background Xentuzumab—a humanised IgG1 monoclonal antibody—binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xentuzumab plus eve

Externí odkaz: https://doaj.org/article/1117dc67dd994a8f8f4c31719c73a41f

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Autor: Luis, Fein, Gonzalo, Gomez Abuin, Diego, Kaen, Ruben, Kowalwszyn, Matias, Molina, Mirta, Varela, Sally, Baron-Hay, Stephen, Begbie, Philip, Clingan, Sherene, Loi, Dhanusha, Sabanathan, Andrea, Gombos, Donatienne, Taylor, Carlos, Barrios, Leandro, Brust, Fabiano, Costa, Ruffo, de Freitas Junior, Roberto, Hegg, Domicio Carvalho, Lacerda, Fernando Cezar Toniazzi, Lissa, Roberto Odebrecht, Rocha, Antonio Orlando, Scalabrini Neto, Felipe, Silva, David, Cescon, Danielle, Charpentier, Cristiano, Ferrario, Xinni, Song, Joanne, Yu, Alejandro, Acevedo, Carlos, Gallardo, Claudio, Salas, Cesar, Sanchez, Eduardo, Yanez, Alvaro, Gomez Diaz, Jesus, Sanchez, Petra, Holeckova, Zdenek, Kral, Bohuslav, Melichar, Katarina, Petrakova, Jana, Prausova, Vesna, Glavicic, Erik, Jakobsen, Jeanette, Jensen, Soren, Linnet, Tamas, Lorincz, Herve, Bonnefoi, Isabelle, Desmoulins, Anthony, Goncalves, Anne-Claire, Hardy-Bessard, Luis, Teixeira, Jens-Uwe, Blohmer, Peter, Fasching, Dirk, Forstmeyer, Nadia, Harbeck, Jens, Huober, Anna, Kaczerowsky Flores de Sousa, Christian, Kurbacher, Sibylle, Loibl, Diana, Lueftner, Tjoung-Won, Park-Simon, Raquel Von, Schumann, Pauline, Wimberger, Louis, Chow, Ava, Kwong, Kai Cheong Roger, Ngan, Peter, Arkosy, Tibor, Csoszi, Zsuzsanna, Kahan, Laszlo, Landherr, Karoly, Mahr, Gabor, Rubovszky, John, Crown, Catherine, Kelly, Seamus, O'Reilly, Saverio, Cinieri, Antonietta, DAlessio, Enrico, Ricevuto, Tomoyuki, Aruga, Takaaki, Fujii, Kenichi, Inoue, Takashi, Ishikawa, Yoshinori, Ito, Tsutomu, Iwasa, Hiroji, Iwata, Yoshimasa, Kosaka, Koji, Matsumoto, Yasuo, Miyoshi, Hirofumi, Mukai, Seigo, Nakamura, Naoki, Niikura, Shoichiro, Ohtani, Akihiko, Osaki, Yasuaki, Sagara, Eiji, Suzuki, Masato, Takahashi, Yuko, Tanabe, Kenji, Tamura, Koichiro, Tsugawa, Junichiro, Watanabe, Naohito, Yamamoto, Yutaka, Yamamoto, Teruo, Yamauchi, Anita, Bustam, Mastura, Md Yusof, Angel, Gomez Villanueva, Alejandro, Juarez Ramiro, Jorge, Martinez Rodriguez, Flavia, Morales-Vasquez, Jessica, Reyes Contreras, Karin, Beelen, Vivianne, Tjan-Heijnen, David, Porter, Ewa, Chmielowska, Ewa, Nowakowska-Zajdel, Zbigniew, Nowecki, Barbara, Radecka, Joanna, Streb, Cezary, Szczylik, Rafal, Tarnawski, Bogdan, Zurawski, Alexander, Arkhipov, Natalia, Fadeeva, Oleg, Lipatov, Andrey, Meshcheryakov, Vladimir, Moiseyenko, Guzel, Mukhametshina, Jin Hee, Ahn, Seock-Ah, Im, Keun Seok, Lee, Kwong Hwa, Park, Yeon Hee, Park, Begona, Bermejo de las Heras, Javier, Cortes, Josefina, Cruz Jurado, Luis, de la Cruz Merino, Jose, Garcia Saenz, Maria, Gion, Esther, Holgado, Esther, Zamora Adelantado, Chien-Ting, Liu, Mei-Ching, Liu, Chiun-Sheng, Huang, Chao-Jung, Tsao, Ling-Ming, Tseng, Cagatay, Arslan, Gul, Basaran, Irfan, Cicin, Erhan, Gokmen, Seyda, Gunduz, Nil, Molinas Mandel, Mustafa, Ozguroglu, Ozgur, Ozyilkan, Sinan, Yavuz, Steve, Chan, Janine, Graham, Iain, MacPherson, Peter, Schmid, Nicholas, Turner, Mark, Tuthill, Christopher, Twelves, Duncan, Wheatley, Hryhoriy, Adamchuk, Oleksandr, Berzoy, Igor, Bondarenko, Oleksii, Kolesnik, Olena, Kolesnik, Hanna, Komisarenko, Anna, Kryzhanivska, Iurii, Leshchenko, Alla, Nasonova, Natalya, Otchenash, Olga, Ponomarova, Andrii, Rusyn, Sergii, Shevnya, Yaroslav, Shparyk, Dmytro, Trukhin, Grygorii, Ursol, Ihor, Vynnychenko, Sibel, Blau, Madhu, Chaudhry, Michael, Chung, Patrick, Cobb, Scott, Cole, Jennifer, Diamond, Keerthi, Gogineni, Jeffrey, Hargis, Kent, Hoskins, William, Irvin, Randa, Loutfi, Janice, Lu, Raul, Mena, Susan, Moore, Rita, Nanda, Ira, Oliff, Coral, Omene, Timothy, Panella, Amit, Panwalkar, Brian, Patson, Hope, Rugo, Irina, Rybalova, Michael, Schleider, Robert, Siegel, Michael, Simon, Laura, Stampleman, Bradley, Sumrall, Michaela, Tsai, Frances, Valdes-Albini, Cortes, Javier ^*, Cescon, David W, Rugo, Hope S, Nowecki, Zbigniew, Im, Seock-Ah, Yusof, Mastura Md, Gallardo, Carlos, Lipatov, Oleg, Barrios, Carlos H, Holgado, Esther, Iwata, Hiroji, Masuda, Norikazu, Otero, Marco Torregroza, Gokmen, Erhan, Loi, Sherene, Guo, Zifang, Zhao, Jing, Aktan, Gursel, Karantza, Vassiliki, Schmid, Peter

Publikováno v: In The Lancet 5-11 December 2020 396(10265):1817-1828

Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)

Autor: Sung-Bae Kim, Jae Hong Seo, Jin-Hee Ahn, Tae-Yong Kim, Seok Yun Kang, Joohyuk Sohn, Yaewon Yang, Kyong Hwa Park, Yong Wha Moon, Seungtaek Lim, Myoung Joo Kang, Koung Eun Yoon, Hyun Ju Cho, Keun Seok Lee

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 13 (2021)

Background: Standard intravenous (IV) paclitaxel is associated with hypersensitivity/toxicity. Alternative IV formulations have improved tolerability but still require frequent hospital visits and IV infusion. DHP107 is a novel oral formulation of pa

Externí odkaz: https://doaj.org/article/d67c1aea2ed64ac8bad679b39788b980